Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | CCR5 | P51681 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18711380 | 0.98 | KMT2A (0.56) | KMT2AMEN1ALDH1A1MAPK1CYP1A2 | |
| SCHEMBL30202554 | 0.92 | CYP1A2 (0.57) | KMT2AMEN1ALDH1A1MAPK1CYP1A2 | |
| SCHEMBL18701626 | 0.81 | MEN1 (0.53) | KMT2AMEN1ALDH1A1MAPK1EPHX1 | |
| SCHEMBL329764 | 0.79 | ALDH1A1 (0.57) | KMT2AMEN1ALDH1A1MAPK1CYP1A2 | |
| SCHEMBL1520440 | 0.79 | IDO1 (0.50) | KMT2AMEN1ALDH1A1MAPK1EPHX1 | |
| SCHEMBL3460774 | 0.78 | SMYD3 (0.56) | KMT2AMEN1ALDH1A1MAPK1CYP1A2 | |
| SCHEMBL23357102 | 0.78 | RIPK1 (0.50) | KMT2AMEN1ALDH1A1MAPK1LMNA | |
| SCHEMBL20302316 | 0.78 | RIPK1 (0.50) | KMT2AMEN1ALDH1A1MAPK1LMNA | |
| SCHEMBL20217167 | 0.78 | GAA (0.50) | KMT2AMEN1ALDH1A1MAPK1EPHX1 | |
| SCHEMBL20302317 | 0.78 | RIPK1 (0.50) | KMT2AMEN1ALDH1A1MAPK1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1937659-B1 | CYCLIC N-[1,3,4]-THIADIAZOL-2-YL-BENZENE SULFONAMIDES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI AVENTIS (FR) | 2010-11-10 | — | — | EP | disclosed |
| US-7683181-B2 | Cyclic N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides, pharmaceutical compositions and methods for the therapeutic use thereof | SANOFI-AVENTIS (FR) | 2010-03-23 | — | — | US | disclosed |
| US-20080280959-A1 | CYCLIC N-[1,3,4]-THIADIAZOL-2-YL-BENZENE SULFONAMIDES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THE THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2008-11-13 | — | — | US | disclosed |
| EP-1937659-A1 | CYCLIC N-[1 ,3,4]-THIADIAZOL-2-YL-BENZENE SULFONAMIDES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | Sanofi-Aventis (FR) | 2008-07-02 | — | — | EP | disclosed |
| WO-2007039173-A1 | CYCLIC N-[1 ,3,4]-THIADIAZOL-2-YL-BENZENE SULFONAMIDES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (DE) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280959-A1 | CYCLIC N-[1,3,4]-THIADIAZOL-2-YL-BENZENE SULFONAMIDES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THE THERAPEUTIC USE THEREOF | PPARD, GPR119, PPARG | KMT2A 3679/4885MEN1 4660/4885ALDH1A1 1628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.